Skip to main content

Tiny bubbles in your body could be better at fighting cancer than chemotherapy

Extracellular Vesicles
Tiny, bubble-like extracellular vesicles (in red) targeting breast cancer cells (in blue) in mice. Michigan State University

Over the past several years, a number of advancements have been made in the world of cancer research, including an artificial beauty spot that could warn you of cancer before symptoms emerge that can be used for early cancer detection and a light-emitting implant that can be used to “zap” tumors.

Recommended Videos

Now new research suggests that tiny bubbles that already exist in the human body might potentially be used to treat cancer — and could work better than chemotherapy.

Masamitsu Kanada, an assistant professor of pharmacology and toxicology at Michigan State University’s Institute for Qualitative Health Science and Engineering has improved a therapeutic approach to delivering genes that can convert certain drugs into toxic agents that can be used to target cancerous tumors.

Essentially, healthy cells in our bodies are always producing “tiny bubbles” called extracellular vesicles (EVs) that transfer generic material like your DNA to other cells. Kanada thinks the nano-sized particles could also be used to transport therapeutic drugs and genes that target cancer cells. His work was recently published in the American Association for Cancer Research.

The research was done through Michigan State University along with Stanford University.

The drugs start out as inactive compounds when they’re put in the body, but when they metabolize in the body, they’re activated and can immediately start fighting diseases like cancer — or even just ease the pain of a headache. 

The difference between the drug and those currently on the market is simply how the drugs are transported to your body. In the case of cancer, the “tiny bubble” method was proven to be 14 times more effective at drug delivery in mice, and it was also more successful at actually killing cancerous tumors.

“Conventional chemotherapy isn’t able to differentiate between tumors and normal tissue, so it attacks it all,” Kanada said in a statement. “This non-specificity can cause severe side effects and insufficient drug concentration in tumors.”

Ultimately the method could help minimize the risk of unwanted immune responses that come with other gene therapies.

A clinical trial of the method, which is separate from Kanada’s work, is expected to begin in the United States soon.

Please enable Javascript to view this content

Emily Price
Former Digital Trends Contributor
Emily is a freelance writer based in San Francisco. Her book "Productivity Hacks: 500+ Easy Ways to Accomplish More at…
Google just gave vision to AI, but it’s still not available for everyone
Gemini Live App on the Galaxy S25 Ultra broadcast to a TV showing the Gemini app with the camera feature open

Google has just officially announced the roll out of a powerful Gemini AI feature that means the intelligence can now see.

This started in March as Google began to show off Gemini Live, but it's now become more widely available.

Read more
This modular Pebble and Apple Watch underdog just smashed funding goals
UNA Watch

Both the Pebble Watch and Apple Watch are due some fierce competition as a new modular brand, UNA, is gaining some serous backing and excitement.

The UNA Watch is the creation of a Scottish company that wants to give everyone modular control of smartwatch upgrades and repairs.

Read more
Tesla, Warner Bros. dodge some claims in ‘Blade Runner 2049’ lawsuit, copyright battle continues
Tesla Cybercab at night

Tesla and Warner Bros. scored a partial legal victory as a federal judge dismissed several claims in a lawsuit filed by Alcon Entertainment, a production company behind the 2017 sci-fi movie Blade Runner 2049, Reuters reports.
The lawsuit accused the two companies of using imagery from the film to promote Tesla’s autonomous Cybercab vehicle at an event hosted by Tesla CEO Elon Musk at Warner Bros. Discovery (WBD) Studios in Hollywood in October of last year.
U.S. District Judge George Wu indicated he was inclined to dismiss Alcon’s allegations that Tesla and Warner Bros. violated trademark law, according to Reuters. Specifically, the judge said Musk only referenced the original Blade Runner movie at the event, and noted that Tesla and Alcon are not competitors.
"Tesla and Musk are looking to sell cars," Reuters quoted Wu as saying. "Plaintiff is plainly not in that line of business."
Wu also dismissed most of Alcon's claims against Warner Bros., the distributor of the Blade Runner franchise.
However, the judge allowed Alcon to continue its copyright infringement claims against Tesla for its alleged use of AI-generated images mimicking scenes from Blade Runner 2049 without permission.
Alcan says that just hours before the Cybercab event, it had turned down a request from Tesla and WBD to use “an icononic still image” from the movie.
In the lawsuit, Alcon explained its decision by saying that “any prudent brand considering any Tesla partnership has to take Musk’s massively amplified, highly politicized, capricious and arbitrary behavior, which sometimes veers into hate speech, into account.”
Alcon further said it did not want Blade Runner 2049 “to be affiliated with Musk, Tesla, or any Musk company, for all of these reasons.”
But according to Alcon, Tesla went ahead with feeding images from Blade Runner 2049 into an AI image generator to yield a still image that appeared on screen for 10 seconds during the Cybercab event. With the image featured in the background, Musk directly referenced Blade Runner.
Alcon also said that Musk’s reference to Blade Runner 2049 was not a coincidence as the movie features a “strikingly designed, artificially intelligent, fully autonomous car.”

Read more